v3.26.1
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2026
GlaxoSmithKline LLC [Member]  
Summary of Expenses Incurred by Company

Expenses incurred by the Company related to the GSK License were recorded as follows (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Cost of license and royalty revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Royalties on net sales of Zolgensma and Itvisma

 

$

760

 

 

$

5,204

 

 

$

1,809

 

 

$

7,786

 

Settlement payment

 

 

 

 

 

 

 

 

10,000

 

 

 

 

Other

 

 

136

 

 

 

5

 

 

 

140

 

 

 

243

 

Total cost of license and royalty revenues

 

 

896

 

 

 

5,209

 

 

 

11,949

 

 

 

8,029

 

General and administrative

 

 

48

 

 

 

53

 

 

 

79

 

 

 

107

 

 

 

$

944

 

 

$

5,262

 

 

$

12,028

 

 

$

8,136